KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Intangibles (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Intangibles for 12 consecutive years, with $109.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Intangibles changed N/A year-over-year to $109.4 million, compared with a TTM value of $109.4 million through Sep 2025, changed N/A, and an annual FY2022 reading of $145.0 million, down 2.29% over the prior year.
  • Intangibles was $109.4 million for Q3 2025 at Travere Therapeutics, up from $106.9 million in the prior quarter.
  • Across five years, Intangibles topped out at $162.9 million in Q1 2023 and bottomed at $106.9 million in Q3 2023.
  • Average Intangibles over 4 years is $139.4 million, with a median of $148.4 million recorded in 2021.
  • The sharpest move saw Intangibles dropped 3.69% in 2021, then dropped 2.29% in 2022.
  • Year by year, Intangibles stood at $148.4 million in 2021, then fell by 2.29% to $145.0 million in 2022, then dropped by 26.29% to $106.9 million in 2023, then increased by 2.37% to $109.4 million in 2025.
  • Business Quant data shows Intangibles for TVTX at $109.4 million in Q3 2025, $106.9 million in Q3 2023, and $154.5 million in Q2 2023.